Latest Bcl-2 Stories
Gemin X Pharmaceuticals announced today that clinical data from a Phase 1/2 study of obatoclax (GX15-070), the Company's innovative pan Bcl-2 inhibitor, will be presented during The 26th Chemotherapy Foundation Symposium being held in New York City from November 4 - 8, 2008.
Pre-clinical studies presented at the 9th International Conference on Membrane Redox Systems in Wellington New Zealand this week demonstrate that Novogen's NV-128 (a novel mTOR inhibitor), when used in combination with the Marshall Edwards, Inc.'s Phase III anti-ovarian cancer drug, phenoxodiol, produces potent synergistic anti-cancer activity against non-small cell lung carcinoma cell lines (NSCLC).
Gemin X, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced that one of its lead oncology candidates, obatoclax, has demonstrated biological and anti-cancer activity in heavily pre-treated patients with advanced chronic lymphocytic leukemia (CLL).
By Park, Chung S Cho, Kyongshin; Bae, Dong R; Joo, Nam E; Kim, Hyung H; Mabasa, Lawrence; Fowler, Andrea W Abstract Lipotropes (methyl group containing nutrients, including methionine, choline, folate, and vitamin B12) are dietary methyl donors and cofactors that are involved in one-carbon metabolism, which is important for genomic DNA methylation reactions and nucleic acid synthesis.
Gemin X, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced that the United States Patent & Trademark Office issued to Gemin X a patent protecting the composition of matter of obatoclax through 2025 - U.S. Patent No. 7,425,553.
By Blankenberg, Francis G After several decades of debate, it is now widely acknowledged that apoptosis, also known as programmed cell death, is central to homoeostasis and normal development and physiology in all multicellular organisms, including humans.
In an act of ultimate self-sacrifice, millions of human cells commit suicide every day, making your life better by their death.
The discovery of how the activities of the protein p53 initiate signals that trigger cell suicide offers critical insights for developing new anti-cancer drugs, according to investigators from St. Jude Children's Research Hospital. A report on this work appears in the September 9 issue of Science.
- Emitting flashes of light; glittering.